Neurobiological Technologies, Inc. (NTII) Announces Dividend of $0.05 Per Share
12/17/2012 9:39:08 AM
More...
|
Neurobiological Technologies, Inc. (NTII) Announces Extraordinary Dividend of $0.18 per Share Company also Announces Timing and Plans to Voluntarily Delist from the Nasdaq Capital Market and Initiate Dissolution Process
11/23/2009 9:52:26 AM
More...
|
Neurobiological Technologies, Inc. (NTII) Announces Intent to File Form 25 to Delist Common Stock From the The Nasdaq Stock Market -- New York Capital Market
10/20/2009 11:24:20 AM
More...
|
Neurobiological Technologies, Inc. (NTII) Board Approves Liquidation Plan
9/1/2009 7:56:58 AM
More...
|
Neurobiological Technologies, Inc. (NTII) Announces Termination of its License and Cooperation Agreement with Merz Pharmaceuticals, LLC and Children's Medical Center
8/12/2009 6:43:47 AM
More...
|
Celtic Pharma Announces Results of XERECEPT(R) Phase 3 Clinical Program
6/1/2009 11:30:58 AM
More...
|
Neurobiological Technologies, Inc. (NTII) Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
5/4/2009 7:54:45 AM
More...
|
Neurobiological Technologies, Inc. (NTII) Announces Appointment of William A. Fletcher as Acting CEO
2/4/2009 7:29:12 AM
More...
|
Neurobiological Technologies, Inc. (NTII) Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
2/3/2009 8:26:16 AM
More...
|
Neurobiological Technologies, Inc. (NTII) Ends Stroke Drug Development; Cuts Jobs
1/13/2009 6:32:44 AM
More...
|
|